ClinicalTrials.gg
CompletedNCT05564039SURPASS-SWITCHUpdated Aug 3, 2025Results posted

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

A Phase 4 interventional study of Tirzepatide and Dulaglutide in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 38 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
17th of 43
282 · median 160
Started
2022
with 3 others
Phase 4
10 of 43
4 open now
Registered
24th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 17th largest by enrollment, is one of 4 that started in 2022, is one of 10 in phase 4, and was the 24th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes
  • Have ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol)
  • Are currently on a stable dose of dulaglutide weekly (0.75 mg or 1.5 mg) for at least 6 months prior to screening.
  • No treatment with oral antihyperglycemic medication (OAM), or on a stable dose of up to 3 OAMs, which may include metformin, sodium glucose cotransporter-2 inhibitors (SGLT-2i), and/or sulfonylurea, for at least 3 months before screening.
  • Have had stable body weight (±5%) during the 90 days preceding screening
  • Have ≥25 kilogram/square meter (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes
  • Have a history of chronic or acute pancreatitis
  • Have a history of

    • proliferative diabetic retinopathy, or
    • diabetic maculopathy, or
    • nonproliferative diabetic retinopathy that requires acute treatment.
  • Have any of these cardiovascular (CV) conditions within 60 days prior to screening:

    • acute myocardial infarction,
    • cerebrovascular accident (stroke), or
    • hospitalization due to congestive heart failure (CHF).
  • Have New York Heart Assocation () Functional Classification Class IV CHF
  • Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
  • Have within 90 days prior to screening received treatment with medications intended to promote weight loss. This includes prescribed, over-the-counter, or alternative remedies
  • Have an estimated (eGFR) \<30 mL/minute/1.73 m2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label)
  • Have been treated with insulin prior to screening

    • Exception: use of insulin for gestational diabetes or short-term use (\<14 days) for acute conditions such as acute illness, hospitalization, or elective surgery.
  • Have a history of reduction of dose of dulaglutide, due to intolerability, without successful reescalation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
282 participants (actual)

Study arms

  • Experimental
    15 Milligram (mg) Tirzepatide or Maximum Tolerated Dose (MTD)

    Participants received tirzepatide administered as subcutaneous (SC) injection via a single-dose pen (SDP) once weekly (QW) for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5mg to 15 mg) until 15 mg or MTD was reached.

    Drug: Tirzepatide

  • Active comparator
    4.5 mg Dulaglutide or MTD

    Participants received dulaglutide administered as SC injection via a SDP QW for 40 weeks. The starting dose of dulaglutide was either 1.5 mg QW, which increased by 1.5 mg every 4 weeks (1.5 mg to 3 mg to 4.5 mg) until 4.5 mg or MTD was reached, or 3.0 mg QW, which increased to 4.5 mg after 4 weeks or until MTD was reached.

    Drug: Dulaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c

    HbA1c is the glycated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 40

Secondary outcomes

  1. Change From Baseline in Body Weight

    LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Baseline HbA1c Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 40

  2. Percentage of Participants Who Achieved HbA1c <7%

    The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing endpoint measures are imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for Baseline HbA1c Value, Baseline SGLT2i use(Yes/No), Treatment, Visit, and Treatment by Visit interaction.

    Time frame: Week 40

  3. Percentage of Participants Who Achieved HbA1c <=6.5%

    The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Logistic regression model was used with missing endpoint measures imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for baseline HbA1c, geographic region 1, number of background OAMs in group 1, dulaglutide dose at screening, and treatment as factors.

    Time frame: Week 40

  4. Percentage of Participants Who Achieved HbA1c <5.7%

    The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Logistic regression model was used with missing endpoint measures imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for baseline HbA1c, geographic region 1, number of background OAMs in group 1, dulaglutide dose at screening, and treatment as factors.

    Time frame: Week 40

  5. Percentage of Participants Who Achieve Weight Loss From Baseline of ≥5%

    Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HBA1C Group + Treatment + Time + Treatment\*Time.

    Time frame: Week 40

  6. Percentage of Participants Who Achieve Weight Loss From Baseline of ≥10%

    Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HBA1C Group + Treatment + Time + Treatment\*Time.

    Time frame: Week 40

  7. Percentage of Participants Who Achieve Weight Loss From Baseline of ≥15%

    Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HBA1C Group + Treatment + Time + Treatment\*Time.

    Time frame: Week 40

  8. Percentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5% & Weight Loss >=10% & No-Hypoglycemia)

    A composite endpoint is defined as HbA1c ≤ 6.5%, weight loss ≥ 10%, and no hypoglycemia, defined as blood glucose (BG) \<3.0 millimole/liter (mmol/L) and/or severe hypoglycemia. Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: For HbA1c: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Treatment + Time + Treatment\*Time. For Weight: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HbA1c Group + Treatment + Time + Treatment\*Time.

    Time frame: Week 40

  9. Change From Baseline in Fasting Serum Glucose (FSG)

    LSMean was calculated using the ANCOVA model for endpoint measures: Variable = Baseline + A1CGR1 + DULDSCRN + OAMGR1 + REGION1 + Treatment (Type I sum of squares).

    Time frame: Baseline, Week 40

  10. Change From Baseline in Waist Circumference

    LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Baseline HbA1c Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 40

  11. Change From Baseline in Body Mass Index (BMI)

    Change from Baseline in BMI is presented. LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Baseline HbA1c Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 40

  12. Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite CT) - Physical Functioning Score

    The IWQOL-Lite-CT is a 20-item, obesity-specific PRO (patient-reported outcome) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial (13 items). The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning. This endpoint shows results for 'physical function domain.'

    Time frame: Baseline, Week 40

07

Results

Posted Aug 3, 2025

Participant flow

Participant flow — Overall Study
Milestone15 Milligram (mg) Tirzepatide or Maximum Tolerated Dose (MTD)4.5 mg Dulaglutide or MTD
Started139143
Received at least 1 dose of study drug139143
Completed129134
Not completed109
Withdrew: Adverse event10
Withdrew: Death11
Withdrew: Lost to follow-up32
Withdrew: Withdrawal by subject20
Withdrew: Inadvertent enrollment36

Outcome measures

PrimaryChange From Baseline in HbA1c

HbA1c is the glycated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c
percentage of HbA1c15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Change From Baseline in HbA1c-1.59 ± 0.073-0.69 ± 0.074
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · Mixed Models Analysis · p = <0.0001 · Ls mean difference (final values): -0.90 · 95% CI -1.10 to -0.69
SecondaryChange From Baseline in Body Weight

LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Baseline HbA1c Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Body Weight
kilograms (kg)15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Change From Baseline in Body Weight-11.0 ± 0.48-3.6 ± 0.49
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · Mixed Models Analysis · p = <.0001 · Ls mean difference (final values): -7.4 · 95% CI -8.7 to -6.0
SecondaryPercentage of Participants Who Achieved HbA1c <7%

The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing endpoint measures are imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for Baseline HbA1c Value, Baseline SGLT2i use(Yes/No), Treatment, Visit, and Treatment by Visit interaction.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HbA1c <7%
percentage of participants15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Percentage of Participants Who Achieved HbA1c <7%84.2152.38
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · Regression, Logistic · p = <0.0001 · Odds ratio (or): 7.13 · 95% CI 3.82 to 13.32
SecondaryPercentage of Participants Who Achieved HbA1c <=6.5%

The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Logistic regression model was used with missing endpoint measures imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for baseline HbA1c, geographic region 1, number of background OAMs in group 1, dulaglutide dose at screening, and treatment as factors.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HbA1c <=6.5%
percentage of participants15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Percentage of Participants Who Achieved HbA1c <=6.5%73.8822.73
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · Regression, Logistic · p = <0.0001 · Odds ratio (or): 12.24 · 95% CI 6.51 to 23.02
SecondaryPercentage of Participants Who Achieved HbA1c <5.7%

The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Logistic regression model was used with missing endpoint measures imputed by predictions from an MMRM analysis model using observed data in the efficacy analysis set and adjusted for baseline HbA1c, geographic region 1, number of background OAMs in group 1, dulaglutide dose at screening, and treatment as factors.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HbA1c <5.7%
percentage of participants15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Percentage of Participants Who Achieved HbA1c <5.7%21.642.27
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · Regression, Logistic · p = <0.0001 · Odds ratio (or): 15.34 · 95% CI 4.58 to 51.36
SecondaryPercentage of Participants Who Achieve Weight Loss From Baseline of ≥5%

Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HBA1C Group + Treatment + Time + Treatment\*Time.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Weight Loss From Baseline of ≥5%
percentage of participants15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Percentage of Participants Who Achieve Weight Loss From Baseline of ≥5%84.3337.40
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · Regression, Logistic · p = <0.0001 · Odds ratio (or): 9.31 · 95% CI 5.11 to 16.98
SecondaryPercentage of Participants Who Achieve Weight Loss From Baseline of ≥10%

Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HBA1C Group + Treatment + Time + Treatment\*Time.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Weight Loss From Baseline of ≥10%
percentage of participants15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Percentage of Participants Who Achieve Weight Loss From Baseline of ≥10%58.216.87
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · Regression, Logistic · p = <0.0001 · Odds ratio (or): 19.35 · 95% CI 9.07 to 41.30
SecondaryPercentage of Participants Who Achieve Weight Loss From Baseline of ≥15%

Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HBA1C Group + Treatment + Time + Treatment\*Time.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Weight Loss From Baseline of ≥15%
percentage of participants15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Percentage of Participants Who Achieve Weight Loss From Baseline of ≥15%27.610.76
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · Regression, Logistic · p = <0.0001 · Odds ratio (or): 35.83 · 95% CI 7.18 to 178.89
SecondaryPercentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5% & Weight Loss >=10% & No-Hypoglycemia)

A composite endpoint is defined as HbA1c ≤ 6.5%, weight loss ≥ 10%, and no hypoglycemia, defined as blood glucose (BG) \<3.0 millimole/liter (mmol/L) and/or severe hypoglycemia. Missing endpoint measures are imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures: For HbA1c: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Treatment + Time + Treatment\*Time. For Weight: Variable = Baseline + Geographic Region 1 + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Baseline HbA1c Group + Treatment + Time + Treatment\*Time.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5% & Weight Loss >=10% & No-Hypoglycemia)
percentage of participants15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Percentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5% & Weight Loss >=10% & No-Hypoglycemia)46.624.58
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · Regression, Logistic · p = <0.0001 · Odds ratio (or): 20.44 · 95% CI 8.40 to 49.77
SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

LSMean was calculated using the ANCOVA model for endpoint measures: Variable = Baseline + A1CGR1 + DULDSCRN + OAMGR1 + REGION1 + Treatment (Type I sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · millimole per liter (mmol/L)
Change From Baseline in Fasting Serum Glucose (FSG)
millimole per liter (mmol/L)15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Change From Baseline in Fasting Serum Glucose (FSG)-2.00 ± 0.149-1.10 ± 0.150
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · ANCOVA · p = <0.001 · Ls mean difference (final values): -0.90 · 95% CI -1.32 to -0.49
SecondaryChange From Baseline in Waist Circumference

LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Baseline HbA1c Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · centimeter (cm)
Change From Baseline in Waist Circumference
centimeter (cm)15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Change From Baseline in Waist Circumference-8.2 ± 0.94-3.1 ± 0.97
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · Mixed Models Analysis · p = 0.0002 · Ls mean difference (final values): -5.1 · 95% CI -7.8 to -2.5
SecondaryChange From Baseline in Body Mass Index (BMI)

Change from Baseline in BMI is presented. LSMean was calculated using MMRM for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Baseline HbA1c Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Kilogram per square meter (kg/m^2)
Change From Baseline in Body Mass Index (BMI)
Kilogram per square meter (kg/m^2)15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Change From Baseline in Body Mass Index (BMI)-3.9 ± 0.17-1.3 ± 0.18
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · Mixed Models Analysis · p = <0.0001 · Ls mean difference (final values): -2.6 · 95% CI -3.1 to -2.1
SecondaryChange From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite CT) - Physical Functioning Score

The IWQOL-Lite-CT is a 20-item, obesity-specific PRO (patient-reported outcome) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial (13 items). The IWQOL-Lite-CT provides composite scores for each domain, as well as a total score, all ranging from 0 to 100. Higher scores reflect better levels of functioning. This endpoint shows results for 'physical function domain.'

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · score on a scale
Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite CT) - Physical Functioning Score
score on a scale15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite CT) - Physical Functioning Score11.8 ± 1.777.8 ± 1.91
Statistical analysis
  • 15 mg Tirzepatide or MTD vs 4.5 mg Dulaglutide or MTD · ANCOVA · p = 0.1181 · Ls mean difference (final values): 4.1 · 95% CI -1.0 to 9.2

Adverse events

Collected over Baseline up to week 44. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
15 mg Tirzepatide or MTD1/139 (0.7%)10/139 (7.2%)77/139 (55.4%)
4.5 mg Dulaglutide or MTD1/143 (0.7%)10/143 (7%)79/143 (55.2%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
Event15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
Ovarian adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/640/72
ArrhythmiaCardiac disorders1/1390/143
Microvascular coronary artery diseaseCardiac disorders1/1390/143
Myocardial infarctionCardiac disorders1/1390/143
Inguinal herniaGastrointestinal disorders1/1390/143
AstheniaGeneral disorders1/1390/143
DeathGeneral disorders1/1390/143
OsteoarthritisMusculoskeletal and connective tissue disorders1/1390/143
Ischaemic strokeNervous system disorders1/1390/143
SyncopeNervous system disorders1/1390/143
Most frequent other events
Showing 10 of 15
Most frequent other events
Event15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTD
NauseaGastrointestinal disorders35/13927/143
DiarrhoeaGastrointestinal disorders31/13919/143
NasopharyngitisInfections and infestations14/13912/143
VomitingGastrointestinal disorders9/13914/143
InfluenzaInfections and infestations6/13914/143
ConstipationGastrointestinal disorders12/13911/143
Decreased appetiteMetabolism and nutrition disorders12/1397/143
DyspepsiaGastrointestinal disorders11/1393/143
FatigueGeneral disorders8/1394/143
HeadacheNervous system disorders8/1396/143

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTDTotal
Mean57.9 ± 9.857.3 ± 10.057.6 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTDTotal
Female6472136
Male7571146
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTDTotal
Hispanic or Latino181432
Not Hispanic or Latino181937
Unknown or Not Reported103110213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTDTotal
American Indian or Alaska Native231942
Asian314
Native Hawaiian or Other Pacific Islander000
Black or African American426
White109120229
More than one race011
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTDTotal
Belgium91019
Germany192140
Mexico434891
Romania323163
United States363369
Percentage of Hemoglobin A1c (HbA1c) at Baseline
Percentage of Hemoglobin A1c (HbA1c) at Baseline(Percentage of HbA1c)15 mg Tirzepatide or MTD4.5 mg Dulaglutide or MTDTotal
Mean7.82 ± 0.697.82 ± 0.737.82 ± 0.71
08

Study locations

38 sites
  • ALL Medical Research, LLC
    Cooper City, Florida 33024, United States
  • Metabolic Research Institute, Inc.
    West Palm Beach, Florida 33401, United States
  • NorthShore University Health System
    Skokie, Illinois 60077, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Clinvest Research LLC
    Springfield, Missouri 65807, United States
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma 73069, United States
  • Juno Research
    Houston, Texas 77040, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • Juno Research
    Houston, Texas 77054, United States
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
  • North Hills Family Medicine/North Hills Medical Research
    North Richland Hills, Texas 76180, United States
  • Imelda General Hospital
    Bonheiden, Antwerpen 2820, Belgium
  • Antwerp University Hospital
    Edegem, Antwerpen 2650, Belgium
  • ZNA Jan Palfijn
    Merksem, Flanders 2170, Belgium
  • AZ Nikolaas
    Sint-Niklaas, Oost-Vlaanderen B-9100, Belgium
  • UZ Leuven
    Leuven, Vlaams-Brabant 3000, Belgium
  • Az Damiaan vzw
    Ostend, West-Vlaanderen 8400, Belgium
  • InnoDiab Forschung Gmbh
    Essen, North Rhine-Westphalia 45136, Germany
  • Institut für Diabetesforschung GmbH Münster
    Münster, North Rhine-Westphalia 48145, Germany
  • Studienzentrum Dr. Tasso Bieler
    Riesa, Saxony 01589, Germany
  • RED-Institut GmbH
    Oldenburg in Holstein, Schleswig-Holstein 23758, Germany
  • Medizinisches Versorgungszentrum am Bahnhof Spandau
    Spandau, State of Berlin 13597, Germany
  • Diabeteszentrum Hamburg West
    Hamburg, 22607, Germany
  • Diseno y Planeacion en Investigacion Medica
    Guadalajara, Jalisco 44130, Mexico
  • Unidad de Investigación Clínica y Atención Médica HEPA
    Guadalajara, Jalisco 44670, Mexico
  • Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares
    Mexico City, Mexico City 11650, Mexico
  • Instituto de Diabetes, Obesidad y Nutricion
    Cuernavaca, Morelos 62250, Mexico
  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
    Monterrey, Nuevo León 64460, Mexico
  • Unidad biomedica avanzada monterrey
    Monterrey, Nuevo León 64460, Mexico
  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
    Monterrey, Nuevo León 66460, Mexico
  • Centro de Estudios de Investigacion Metabolicos y Cardiovasculares
    Ciudad Madero, Tamaulipas 89440, Mexico
  • Investigacion En Salud Y Metabolismo Sc
    Chihuahua City, 31217, Mexico
  • Diabdana
    Oradea, Bihor County 410147, Romania
  • Mariodiab Clinic
    Brasov, Brașov County 500097, Romania
  • Geea Medical Easy Diet
    Bucharest, Bucharest 010627, Romania
  • Gama Diamed
    Mangalia, Constanța County 905500, Romania
  • CMI DNBM Dr. Pop Lavinia
    Baia Mare, Maramureş 430222, Romania
  • Clinica Korall
    Satu Mare, 440055, Romania
09

References and documents

Publications

  • Violante-Ortiz R, Rose L, Sharma P, Gomez Valderas E, Chivukula KK, Kwan AY. Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH. BMJ Open Diabetes Res Care. 2026 Mar 30;14(2):e005711. doi: 10.1136/bmjdrc-2025-005711. PubMed 41912265 ↗
  • Billings LK, Winne L, Sharma P, Gomez-Valderas E, Chivukula KK, Kwan AYM. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. Ann Intern Med. 2025 May;178(5):609-619. doi: 10.7326/ANNALS-24-03849. Epub 2025 Apr 4. PubMed 40183678 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jul 2024, 19 months.

Results were first posted in Aug 2025, 1 year after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 19 months is close to that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2022
First posted
Oct 3, 2022
StartActual
Nov 30, 2022
Primary completionActual
Jul 15, 2024
CompletionActual
Aug 12, 2024
Results first posted
Aug 3, 2025
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05564039
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Nov 30, 2022
Primary completion
Jul 15, 2024
Completion
Aug 12, 2024
Results posted
Aug 3, 2025
Last update
Aug 3, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion